Symposium: Pneumonia 2010 - State of the art;Symposium: Pneumonie 2010 - State of the Art

Pneumologie

Volumn 65, Issue 4, 2011, Pages 223-228

  Barten, G ^a   Schutte H ^a   Bals, R ^a   Pletz, M ^a   Rohde, G ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMMUNITY ACQUIRED PNEUMONIA; CONFERENCE PAPER; GERMANY; HUMAN; MEDICAL RESEARCH; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR;

COMMUNITY-ACQUIRED INFECTIONS; FORECASTING; GERMANY; HUMANS; PNEUMONIA; PULMONARY MEDICINE;

EID: 79953797959     PISSN: 09348387     EISSN: 14388790     Source Type: Journal    
DOI: 10.1055/s-0030-1256275     Document Type: Conference Paper

References (45)

1. Schnoor M, Hedicke J, Dalhoff K et al. Approaches to estimate the population-based incidence of community acquired pneumonia. J Infect 2007 55 233-239 (Pubitemid 47248481)
2. Ewig S, Birkner N, Strauss R et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 2009 64 1062-1069
3. Waterer G W., Kessler L A., Wunderink R G. Medium-term survival after hospitalization with community-acquired pneumonia. Am J Respir Crit Care Med 2004 169 910-914 (Pubitemid 38457316)
4. Jokinen C, Heiskanen L, Juvonen H et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol 1993 137 977-988 (Pubitemid 23191065)
5. Kothe H, Bauer T, Marre R et al. Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J 2008 32 139-146
6. Hoffken G, Lorenz J, Kern W et al. Epidemiology, diagnosis, antimicrobial therapy and management of community-acquired pneumonia and lower respiratory tract infections in adults. Guidelines of the Paul-Ehrlich-Society for Chemotherapy, the German Respiratory Society, the German Society for Infectiology and the Competence Network CAPNETZ Germany. Pneumologie 2009 63 e1-e68
7. Baum H von, Welte T, Marre R et al. Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: Diagnosis, incidence and predictors. Eur Respir J 2010 35 598-605
8. Baum H von, Welte T, Marre R et al. Mycoplasma pneumoniae pneumonia revisited within the German Competence Network for Community-acquired pneumonia (CAPNETZ). BMC Infect Dis 2009 9 62
9. Baum H von, Schweiger B, Welte T et al. How deadly is seasonal influenza associated pneumonia? The German Competence Network for Community-acquired pneumonia (CAPNETZ). Eur Respir J 2010 Sep 3 [Epub ahead of print]
10. Barbuddhe S B., Maier T, Schwarz G et al. Rapid identification and typing of listeria species by matrix-assisted laser desorption ionization-time of flight mass spectrometry. Appl Environ Microbiol 2008 74 5402-5407
11. Medini D, Donati C, Tettelin H et al. The microbial pan-genome. Curr Opin Genet Dev 2005 15 589-594 (Pubitemid 41532330)
12. Fine M J., Auble T E., Yealy D M. et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997 336 243-250 (Pubitemid 27044625)
13. Lim W S., van der Eerden M M., Laing R et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003 58 377-382 (Pubitemid 36560938)
14. Ewig S, de Roux A, Bauer T et al. Validation of predictive rules and indices of severity for community acquired pneumonia. Thorax 2004 59 421-427 (Pubitemid 38624749)
15. Bauer T T., Ewig S, Marre R et al. CRB-65 predicts death from community-acquired pneumonia. J Intern Med 2006 260 93-101 (Pubitemid 43894075)
16. Krüger S, Ewig S, Marre R et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008 31 349-355
17. Christ-Crain M, Stolz D, Bingisser R et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006 174 84-93 (Pubitemid 43955248)
18. Krüger S, Ewig S, Giersdorf S et al. Cardiovascular and Inflammatory Biomarkers to Predict Short- and Long-term Survival in Community-acquired Pneumonia. Am J Respir Crit Care Med 2010 182 1426-1434
19. Sorensen T I., Nielsen G G., Andersen P K. et al. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988 318 727-732 (Pubitemid 18090256)
20. Hammerschmidt S. Adherence molecules of pathogenic pneumococci. Curr Opin Microbiol 2006 Feb; 9 (1) 12-20 (Pubitemid 43184332)
21. Agarwal V, Hammerschmidt S. Cdc42 and PI3-kinase-Akt pathway are essential for PspC mediated internalization of pneumococci by respiratory epithelial cells. J Biol Chem 2009 Jul; 17 284 (29) 19 427-19 436
22. Dave S, Carmicle S, Hammerschmidt S et al. Dual roles of PspC, a surface protein of Streptococcus pneumoniae, in binding human secretory IgA and factor H. J Immunol 2004 173 471-477 (Pubitemid 38797374)
23. Hammerschmidt S, Agarwal V, Kunert A et al. The host immune regulator factor H interacts via two contact sites with the PspC protein of Streptococcus pneumoniae and mediates adhesion to host epithelial cells. J Immunol 2007 178 5848-5858 (Pubitemid 46674382)
24. Kadioglu A, Brewin H, Hartel T et al. Pneumococcal protein PavA is important for nasopharyngeal carriage and development of sepsis. Mol Oral Microbiol 2010 25 50-60
25. Noske N, Kammerer U, Rohde M et al. Pneumococcal interaction with human dendritic cells: phagocytosis, survival, and induced adaptive immune response are manipulated by PavA. J Immunol 2009 183 1952-1963
26. Hess C, Herr C, Beisswenger C et al. Myeloid RelA regulates pulmonary host defense networks. Eur Respir J 2010 35 343-352
27. Beisswenger C, Kandler K, Hess C et al. Allergic airway inflammation inhibits pulmonary antibacterial host defense. J Immunol 2006 177 1833-1837 (Pubitemid 44092521)
28. Herr C, Beisswenger C, Hess C et al. Suppression of pulmonary innate host defence in smokers. Thorax 2009 64 144-149
29. Schmeck B, Huber S, Moog K et al. Pneumococci induced TLR- and Rac1-dependent NF-kappaB-recruitment to the IL-8 promoter in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2006 290 L730-L737 (Pubitemid 43725078)
30. Zahlten J, Steinicke R, Opitz B et al. TLR2- and nucleotide-binding oligomerization domain 2-dependent Krüppel-like factor 2 expression downregulates NF-kappa B-related gene expression. J Immunol 2010 185 597-604
31. Fiedler U, Reiss Y, Scharpfenecker M et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006 12 235-239 (Pubitemid 43214752)
32. Witzenrath M, Schütte H et al. Phosphodiesterase 2 inhibition diminished acute lung injury in murine pneumococcal pneumonia. Crit Care Med 2009 Feb; 37 (2) 584-590
33. Pletz M W., Maus U, Krug N et al. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents 2008 32 199-206
34. Ruckinger S, van der Linden M, Reinert R R. et al. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine 2009 27 4136-4141
35. Leroux-Roels I, Borkowski A, Vanwolleghem T et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007 370 580-589 (Pubitemid 47247854)
36. Kumar A, Roberts D, Wood K E. et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006 34 1589-1596 (Pubitemid 43810035)
37. Kumar A, Ellis P, Arabi Y et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009 136 1237-1248
38. Pletz M W., McGee L, Jorgensen J et al. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob Agents Chemother 2004 48 3491-3497 (Pubitemid 39129350)
39. Pletz M W., McGee L, Beall B et al. Interspecies recombination in type II topoisomerase genes is not a major cause of fluoroquinolone resistance in invasive Streptococcus pneumoniae isolates in the United States. Antimicrob Agents Chemother 2005 49 779-780 (Pubitemid 40175695)
40. Pletz M W., van der Linden M, Baum H von et al. Low prevalence of fluoroquinolone resistant strains and resistance precursor strains in Streptococcus pneumoniae from patients with community-acquired pneumonia despite high fluoroquinolone usage. Int J Med Microbiol 2011 301 53-57
41. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005 171 388-416
42. Kollef M H., Shorr A, Tabak Y P. et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005 128 3854-3862 (Pubitemid 43062645)
43. Micek S T., Kollef K E., Reichley R M. et al. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother 2007 51 3568-3573 (Pubitemid 47519345)
44. Ewig S, Welte T, Chastre J et al. Rethinking the concepts of community-acquired and health-care-associated pneumonia. Lancet Infect Dis 2010 10 279-287
45. CAPNETZ STIFTUNG. Projektanträge. http://www.capnetz.de/html/ research/projects/proposal Stand: 1. 10. 2010